/XAIR
XAIR Stock - Beyond Air, Inc.
Healthcare|Medical - DevicesNASDAQ
$0.91-1.67%
$0.02 (-1.67%) • Dec 19
54
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).69
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+9.7%upside
Target: $1.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for XAIR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.90 – $0.92
TARGET (TP)$1.00
STOP LOSS$0.84
RISK/REWARD1:1.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.30
52W High$11.20
52W Low$0.90
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $3.71M | $1.16M | N/A | N/A | $873,000 |
| Gross Profit | $-1,663,000 | $-1,307,000 | $-555,000 | N/A | $873,000 |
| Gross Margin | -44.9% | -112.8% | N/A | N/A | 100.0% |
| Operating Income | $-44,537,000 | $-63,006,000 | $-52,059,000 | $-40,710,000 | $-22,214,000 |
| Net Income | $-46,625,000 | $-60,242,000 | $-55,816,000 | $-43,177,000 | $-22,875,000 |
| Net Margin | -1258.4% | -5197.8% | N/A | N/A | -2620.3% |
| EPS | $-13.77 | $-36.33 | $-37.24 | $-33.64 | $-25.41 |
Company Overview
Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
67%
Hold / Neutral
1
33%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
2 Bullish1 Neutral/Bearish
Price Targets
$12
Average Target
↑ 1216.1% Upside
Now
$10
Low
$12
Average
$15
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 17th 2025 | D. Boral Capital | Initiation | Buy | $11 |
| June 25th 2024 | BTIG Research | Downgrade | Neutral | - |
| July 28th 2023 | Piper Sandler | Initiation | Overweight | $10 |
| June 15th 2023 | BTIG Research | Initiation | Buy | $15 |
Earnings History & Surprises
XAIRBeat Rate
42%
Last 19 quarters
Avg Surprise
-23.4%
EPS vs Estimate
Beats / Misses
8/11
Last 12 quarters
Latest EPS
$-1.25
Q4 2025
EPS Surprise History
Q1 24
+18.0%
$-0.50vs$-0.61
Q2 24
+23.4%
$-0.36vs$-0.47
Q3 24
+6.9%
$-0.27vs$-0.29
Q4 24
+6.7%
$-0.28vs$-0.30
Q1 25
+37.5%
$-0.15vs$-0.24
Q2 25
+35.7%
$-1.80vs$-2.80
Q3 25
-2.0%
$-1.53vs$-1.50
Q4 25
-363.0%
$-1.25vs$-0.27
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 9, 2026 | — | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.27 | $-1.25 | -363.0% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | $-1.50 | $-1.53 | -2.0% | ✗ MISS |
Q2 2025 | Jun 17, 2025 | $-2.80 | $-1.80 | +35.7% | ✓ BEAT |
Q1 2025 | Feb 10, 2025 | $-0.24 | $-0.15 | +37.5% | ✓ BEAT |
Q4 2024 | Nov 11, 2024 | $-0.30 | $-0.28 | +6.7% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-0.29 | $-0.27 | +6.9% | ✓ BEAT |
Q2 2024 | Jun 24, 2024 | $-0.47 | $-0.36 | +23.4% | ✓ BEAT |
Q1 2024 | Feb 12, 2024 | $-0.61 | $-0.50 | +18.0% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.47 | $-0.51 | -8.5% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.46 | $-0.45 | +2.2% | ✓ BEAT |
Q2 2023 | Jun 22, 2023 | $-0.44 | $-0.67 | -52.3% | ✗ MISS |
Q1 2023 | Feb 9, 2023 | $-0.42 | $-0.43 | -2.4% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-0.36 | $-0.40 | -11.1% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-0.28 | $-0.37 | -32.1% | ✗ MISS |
Q2 2022 | Jun 28, 2022 | $-0.24 | $-0.26 | -8.3% | ✗ MISS |
Q1 2022 | Feb 10, 2022 | $-0.25 | $-0.29 | -16.0% | ✗ MISS |
Q4 2021 | Nov 11, 2021 | $-0.25 | $-0.36 | -44.0% | ✗ MISS |
Q3 2021 | Aug 10, 2021 | $-0.19 | $-0.31 | -63.2% | ✗ MISS |
Q2 2021 | Jun 10, 2021 | $-0.33 | $-0.24 | +27.3% | ✓ BEAT |
Latest News
Beyond Air Signs Distribution Deals For LungFit PH
📈 PositiveBenzinga•Dec 17, 2025, 12:36 PM
Beyond Air CFO Doug Larson Resigns; Appoints Duke Drewell As Interim CFO
📉 NegativeBenzinga•Nov 26, 2025, 09:33 PM
D. Boral Capital Maintains Buy on Beyond Air, Maintains $11 Price Target
📈 PositiveBenzinga•Nov 11, 2025, 12:21 PM
Beyond Air Lowers FY2026 Sales Guidance from $12.000M-$16.000M to $8.000M-$10.000M vs $13.117M Est
📉 NegativeBenzinga•Nov 10, 2025, 09:07 PM
Beyond Air Q2 EPS $(1.25) Misses $(0.85) Estimate, Sales $1.818M Miss $2.487M Estimate
📉 NegativeBenzinga•Nov 10, 2025, 09:06 PM
Beyond Air Signs $32M Financing Agreement With Streeterville Capital
📈 PositiveBenzinga•Nov 5, 2025, 01:01 PM
Beyond Air shares are trading lower. The company recently gained FDA Orphan Drug Status for its NeuroNOS.
➖ NeutralBenzinga•Sep 9, 2025, 03:52 PM
Beyond Air Exercises Outstanding Common Warrants For Gross Proceeds Of $3.25M Through Immediate Exercise Of 1.44M Warrants At $2.21/Share; Issues 720K New Warrants At $0.0625 With 5-Year Term
📈 PositiveBenzinga•Sep 8, 2025, 07:57 PM
NeuroNOS shares are trading higher after the company announced the FDA granted Orphan Drug Designation to BA-101 for the treatment of Glioblastoma.
📈 PositiveBenzinga•Sep 8, 2025, 12:51 PM
Beyond Air Says Subsidiary NeuroNOS Granted FDA Orphan Drug Designation For Glioblastoma
📈 PositiveBenzinga•Sep 8, 2025, 12:01 PM
Beyond Air Granted Orphan Designation Status For 7-Nitro-1H-indazole For The Treatment Of Malignant Glioma
📈 PositiveBenzinga•Sep 3, 2025, 01:56 PM
D. Boral Capital Maintains Buy on Beyond Air, Maintains $11 Price Target
📈 PositiveBenzinga•Aug 21, 2025, 11:52 AM
Beyond Air Sales Jump 158 Percent
📈 PositiveThe Motley Fool•Aug 18, 2025, 09:24 PM
Beyond Air granted U.S. patent for treatment of NTM infections using gaseous Nitric Oxide
📈 PositiveSeeking Alpha•Apr 24, 2025, 08:14 PM
Frequently Asked Questions about XAIR
What is XAIR's current stock price?
Beyond Air, Inc. (XAIR) is currently trading at $0.91 per share. The stock has moved -1.67% today.
What is the analyst price target for XAIR?
The average analyst price target for XAIR is $1.00, based on 1 analyst.
What sector is Beyond Air, Inc. in?
Beyond Air, Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is XAIR's market cap?
Beyond Air, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does XAIR pay dividends?
No, Beyond Air, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAEON
AEON Biopharma, Inc.
$1.08
Mkt Cap: $0.0B
BOLT
Bolt Biotherapeutics, Inc.
$5.16
Mkt Cap: $0.0B
CLRB
Cellectar Biosciences, Inc.
$2.68
Mkt Cap: $0.0B
CODX
Co-Diagnostics, Inc.
$0.26
Mkt Cap: $0.0B
IINN
Inspira Technologies Oxy B.H.N. Ltd.
$1.02
Mkt Cap: $0.0B
LFWD
Lifeward Ltd.
$0.65
Mkt Cap: $0.0B
LYRA
Lyra Therapeutics, Inc.
$3.60
Mkt Cap: $0.0B
SINT
Sintx Technologies, Inc.
$3.61
Mkt Cap: $0.0B
TNON
Tenon Medical, Inc.
$1.10
Mkt Cap: $0.0B
TRIB
Trinity Biotech plc
$0.90
Mkt Cap: $0.0B
Explore stocks similar to XAIR for comparison